All In Biotech

NDA 220748 · Avyxa Holdings

Axycis

Cisplatin · Intravenous · Platinum-based Drug

Last checked: Nov 20, 2026Latest source record: Oct 29, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2026

Oct 29, 2026

Approved uses

1

Original approval plus efficacy supplements

Registered trials

4,792

1,209 Phase 3, 731 recruiting

FAERS reports

0

0 serious, 0 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: NEPHROTOXICITY, PERIPHERAL NEUROPATHY, NAUSEA AND VOMITING, AND MYELOSUPPRESSION Nephrotoxicity: AXYCIS can cause severe renal toxicity, including acute renal failure. Severe renal toxicities are dose-related and cumulative. Ensure adequate hydration and monitor renal function and electrolytes. Consider dose reductions or alternative treatments in patients with renal impairment [see Dosage and Administration (2.1) and Warnings and Precautions (5.1) ]. Peripheral Neuropathy: AXYCIS can cause dose-related peripheral neuropathy that becomes more severe with repeated courses of the drug [see Warnings and Precautions (5.2) ]. Nausea and Vomiting: AXYCIS can cause severe nausea and vomiting. Administer pre-treatment and post-treatment antiemetics as clinically indicated [see Dosage and Administration (2.1) and Warnings and Precautions (5.3) ]. Myelosuppression: AXYCIS can cause...

What it is approved for

From the label in effect Nov 12, 2026.

AXYCIS is a platinum-based drug indicated for the treatment of: Advanced testicular cancer ( 1.1 ) Advanced ovarian cancer ( 1.2 ) Advanced bladder cancer ( 1.3 ) 1.1 Advanced Testicular Cancer AXYCIS is indicated for the treatment of advanced testicular cancer. 1.2 Advanced Ovarian Cancer AXYCIS is indicated for the treatment of advanced ovarian cancer. 1.3 Advanced Bladder Cancer AXYCIS is indicated for the treatment of advanced bladder cancer.

Mechanism: Cisplatin is a platinum-based drug that binds to DNA and forms DNA cross-links. These crosslinks inhibit DNA replication and transcription and trigger cytotoxic processes that lead to cell death.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Oct 29, 2026 Original approval · Type 5 - New Formulation or New Manufacturer LabelLetter
1 products under this application
  • AXYCIS · CISPLATIN 50MG/50ML (1MG/ML) · SOLUTION, INTRAVENOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Cisplatin" as an intervention, any sponsor and status, largest first.

All 4,792 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals

No FAERS reports name this application.

FAERS reports by year

By the date FDA received the report.

No reports.

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 11,471 on PubMed

Sponsor: Avyxa Holdings

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.